checkAd
    Startseite > Aktien > Amylyx Pharmaceuticals > Nachrichten
    Amylyx Pharmaceuticals
    Aktie
    ISIN: US03237H1014 WKN: A3DCEY SYM: AMLX Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    1,6400
     
    USD
    -2,38 %
    -0,0400 USD
    Letzter Kurs 02:00:00 Nasdaq
    Geldkurs
    14.06.24
    1,6300
     
    USD
    23.300 STK
    Briefkurs
    14.06.24
    1,6400
     
    USD
    5.100 STK

    Amylyx Pharmaceuticals Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    04.06.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
    09.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
    08.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
    02.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
    10.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
    08.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
    08.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    AMYLYX PHARMACEUTICALS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX
    06.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
    04.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
    14.03.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations
    09.03.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
    08.03.24 · Business Wire (engl.) · Amylyx Pharmaceuticals